CA3128377A1 - Bicyclic pyridine compositions and methods of using the same for cancer therapy - Google Patents

Bicyclic pyridine compositions and methods of using the same for cancer therapy Download PDF

Info

Publication number
CA3128377A1
CA3128377A1 CA3128377A CA3128377A CA3128377A1 CA 3128377 A1 CA3128377 A1 CA 3128377A1 CA 3128377 A CA3128377 A CA 3128377A CA 3128377 A CA3128377 A CA 3128377A CA 3128377 A1 CA3128377 A1 CA 3128377A1
Authority
CA
Canada
Prior art keywords
hydrogen
substituted
unsubstituted
compound
deuterated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3128377A
Other languages
English (en)
French (fr)
Inventor
Igor B. Roninson
Mengqian CHEN
Jing Li
Jiaxin LIANG
Li Zhang
Campbell Mcinnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Senex Biotechnology Inc
Original Assignee
University of South Carolina
Senex Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina, Senex Biotechnology Inc filed Critical University of South Carolina
Publication of CA3128377A1 publication Critical patent/CA3128377A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3128377A 2019-02-01 2020-02-03 Bicyclic pyridine compositions and methods of using the same for cancer therapy Pending CA3128377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800239P 2019-02-01 2019-02-01
US62/800,239 2019-02-01
PCT/US2020/016394 WO2020160537A1 (en) 2019-02-01 2020-02-03 Bicyclic pyridine compositions and methods of using the same for cancer therapy

Publications (1)

Publication Number Publication Date
CA3128377A1 true CA3128377A1 (en) 2020-08-06

Family

ID=71842384

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128377A Pending CA3128377A1 (en) 2019-02-01 2020-02-03 Bicyclic pyridine compositions and methods of using the same for cancer therapy

Country Status (8)

Country Link
US (1) US11572369B2 (enExample)
EP (1) EP3917523B1 (enExample)
JP (1) JP7628252B2 (enExample)
CN (1) CN113677341B (enExample)
AU (1) AU2020216498B2 (enExample)
CA (1) CA3128377A1 (enExample)
ES (1) ES2991429T3 (enExample)
WO (1) WO2020160537A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024193640A1 (zh) * 2023-03-22 2024-09-26 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271723A (en) 1976-11-19 1981-06-09 Caterpillar Tractor Co. Power train with an auxiliary creeper drive system
GB9402029D0 (en) 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
DE60325051D1 (de) 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1764367A1 (en) * 2004-04-12 2007-03-21 Sankyo Company, Limited Thienopyridine derivatives
US20070021927A1 (en) 2005-07-21 2007-01-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Selective resonance of chemical structures
US20070207201A1 (en) 2006-03-06 2007-09-06 Wyeth Liquid and Semi-Solid Pharmaceutical Formulations and Processes
JP2008260693A (ja) * 2007-04-10 2008-10-30 Daiichi Sankyo Co Ltd チエノピリジン−２−カルボキサミド誘導体を含有する医薬組成物
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
EP2489354A1 (en) 2011-02-18 2012-08-22 Vironova AB Pharmaceutical formulation of B220 for topical treatment of herpes
EA027531B1 (ru) 2011-09-13 2017-08-31 Игорь Ронинсон ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB
KR20150023223A (ko) 2012-02-02 2015-03-05 세넥스 바이오테크놀러지 인코포레이티드 Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도
KR20160014568A (ko) * 2012-11-01 2016-02-11 유니버시티 오브 싸우스 캐롤라이나 전립선암을 치료하는 방법
WO2014087240A2 (en) * 2012-12-04 2014-06-12 Dalhousie University Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
WO2014134169A1 (en) * 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
WO2014164543A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2014194245A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
US9937153B2 (en) 2013-08-30 2018-04-10 Merck Sharp & Dohme Ltd. Oral pharmaceutical formulation of omarigliptin
AU2014369834B2 (en) 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US9566280B2 (en) * 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
NZ722345A (en) * 2014-02-14 2018-02-23 Inception 2 Inc Pyrazolone compounds and uses thereof
WO2016018511A2 (en) 2014-06-10 2016-02-04 University Of South Carolina Methods and compositions for treatment of her-positive cancers
JP2017522324A (ja) * 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用
WO2016041618A1 (en) * 2014-09-15 2016-03-24 Merck Patent Gmbh Substituted indazoles and related heterocycles
US20210322651A1 (en) 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
AU2016348659B2 (en) * 2015-11-03 2022-07-28 Apriligen, Inc. Compounds for treatment of hypoproliferative disorders
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
WO2020237014A1 (en) * 2019-05-21 2020-11-26 University Of South Carolina 3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl) thieno [2,3-b] pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same

Also Published As

Publication number Publication date
CN113677341A (zh) 2021-11-19
WO2020160537A1 (en) 2020-08-06
AU2020216498A1 (en) 2021-09-23
CN113677341B (zh) 2024-07-05
US11572369B2 (en) 2023-02-07
EP3917523A4 (en) 2022-10-19
EP3917523C0 (en) 2024-09-11
AU2020216498B2 (en) 2025-08-28
JP2022523742A (ja) 2022-04-26
US20220135583A1 (en) 2022-05-05
ES2991429T3 (es) 2024-12-03
EP3917523A1 (en) 2021-12-08
EP3917523B1 (en) 2024-09-11
JP7628252B2 (ja) 2025-02-10

Similar Documents

Publication Publication Date Title
US11420955B2 (en) Compounds as neuronal histamine receptor-3 antagonists and uses thereof
US9498467B2 (en) Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US12344588B2 (en) Sulfonamide compounds and use thereof
EP3235819B1 (en) Pyrrolopyrimidine compounds useful as jak inhibitors
TW202115065A (zh) Kras突變蛋白抑制劑
JP7757036B2 (ja) Ｋｖ７チャネル活性化剤の構成および使用方法
CN112672997A (zh) 哒嗪酮衍生物
BR112020021569A2 (pt) Inibidor da interação proteína-proteína mll1-wdr5 de fenil triazol
CN102887889B (zh) 杂环取代的嘧啶类化合物
US20220226343A1 (en) 3-amino-4-[4-[4 (dimethylcarbamoyl) phenyl]-1,4-diazepan-1-yl]thieno[2,3-b]pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same
WO2004060400A1 (ja) 上皮成長因子受容体を分子標的とする抗精神病薬
CA3128377A1 (en) Bicyclic pyridine compositions and methods of using the same for cancer therapy
CN108101889A (zh) 氘代n-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
CN108047207A (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
JP2026505349A (ja) 改変されたタンパク質の選択的分解のための化合物および組成物
EP4238975A1 (en) Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
CN121405680A (zh) 取代苯并咪唑衍生物及其制备方法和用途
CA3233231A1 (en) Irhom2 inhibitors and uses thereof
TW202417434A (zh) 用於治療之parp14之靶向蛋白質降解
WO2024227033A1 (en) Heterocyclic compounds as parp1 inhibitors
WO2024022365A1 (zh) 一种Wnt通路抑制剂化合物
CN121471213A (zh) 钠通道调节剂
CN116535390A (zh) pH敏感型4-酰胺哌啶类衍生物、药物组合物及其制备方法和应用
HK40092863A (en) Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
HK40053244A (en) Pyridazinone derivative

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250131

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250708

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250708

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P124 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT AFTER ALLOWANCE (AAA) RECEIVED

Effective date: 20250912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251014

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT AFTER ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251021

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260227

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260318